Back to Journals » Clinical Ophthalmology » Volume 7

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Authors Nielsen SA, McDonald MB, Majmudar PA, Clark L

Received 18 March 2013

Accepted for publication 18 March 2013

Published 15 April 2013 Volume 2013:7 Pages 725—726

DOI https://doi.org/10.2147/OPTH.S45371

Corrigendum
Nielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156.
The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients," contains an inaccurate description of the intraoperative use of medications.

In the Results section it is reported that 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface. We have determined that ambiguity in the design of the electronic case report form resulted in all day-of-surgery drops provided to patients in the LASER suite being reported in the flap interface field. The authors have since clarified with each surgeon who reported intraoperative drug use that the drops were delivered either prior to the flap creation, or following replacement of the flap.
The sentence at the top of page 152 stating: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface" should say: "Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had intraoperative drops applied."

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]